viewAntisense Therapeutics Ltd

Full interview: Antisense Therapeutics further develops therapeutic for Duchenne Muscular Dystrophy with ATL1102

Antisense Therapeutics Limited (ASX:ANP) managing director Mark Diamond updates Proactive on the company’s progress in developing a therapeutic for a severe disease called Duchenne Muscular Dystrophy, or DMD.

The managing director spoke about the importance of the drug ATL1102 that is being progressed through the company’s Phase 2 trial, saying it has shown significant success.

Diamond says some important regulatory interactions necessary for efficient and timely advancement to the next stage of development of ATL1102 are underway.

Quick facts: Antisense Therapeutics Ltd

Price: 0.1 AUD

Market: ASX
Market Cap: $57.4 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antisense Therapeutics Ltd named herein, including the promotion by the Company of Antisense Therapeutics Ltd in any Content on the Site, the...


Venture Minerals says Golden Grove North could host significant body of VMS...

Venture Minerals Limited's (ASX:VMS) Andrew Radonjic sat down with Proactive's Andrew Scott after confirming a volcanic massive sulphide (VMS) system with assays of up to 7% zinc in its maiden drilling at the Orcus prospect within the Golden Grove North Project in WA. All three holes returned...

1 day, 8 hours ago

2 min read